title: Targeting oncogene dependence and resistance.
abstract: Our expanding experience with imatinib mesylate provides instructive lessons on the power and pitfalls of targeted therapy. The often impressive initial clinical responses seen with imatinib in a variety of malignancies inevitably give way to the emergence of resistant disease. Recent findings reveal several mechanisms of resistance and suggest ways to overcome them.
authors.affiliation: Abramson Family Cancer Research Institute, Abramson Cancer Center of the University of Pennsylvania School of Medicine, Department of Medicine, Philadelphia 19104, USA. srhingo@mail.med.upenn.edu
authors.forename: Sunil R
authors.initials: SR
authors.lastname: Hingorani
authors.forename: David A
authors.initials: DA
authors.lastname: Tuveson
mesh_terms: D000483:Alleles; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D045744:Cell Line, Tumor; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D009857:Oncogenes / Q000235:genetics*; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl